ArticleGynecologic oncology2020

Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.

Rafael Gonzalez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.